Cargando…
抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) such as antibodies against programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have shown remarkable efficacies in many subtypes of cancers. However, ICIs may also cause severe immune-related adverse events in the r...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246393/ https://www.ncbi.nlm.nih.gov/pubmed/34157799 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.23 |
_version_ | 1783716304469884928 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) such as antibodies against programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have shown remarkable efficacies in many subtypes of cancers. However, ICIs may also cause severe immune-related adverse events in the recipient patients. Recently, ICI-associated myocarditis have been reported in hundreds of patients worldwide, with a mortality rate of approximately 50% in these cases. This study aims to recapitulate the cardiotoxicity and explore the detoxicifying approaches to attenuate mortality caused by PD-1/PD-L1 inhibitors in healthy mice. METHODS: Six to eight-week-old C57BL/6 mice were inoculated with anti-PD-1 antibody (12.5 μg/g every 5 days for 6 injections), anti-PD-L1 antibody (10 μg/g once a week for 6 weeks), anti-PD-L1 antibody (with the same dosage described above) in combination with levothyroxine (0.25 μg/g, intraperitoneally injected half an hour before anti-PD-L1 antibody injection), or isotype control immunoglobulin IgG (10 μg/g once a week for 6 weeks). The ejection function of the hearts was detected by echocardiography, body temperature and blood pressure were detected by Mouse Monitor(TM) and non-invassive blood pressure minotor, and serum free thyroxine concentration was detected by The enzyme linked immunosorbent assay (ELISA). RESULTS: PD-L1 was expressed at different levels by the cardiomyocytes of the mice. The isotype control immunoglobulin and anti-PD-1 antibody did not cause death of the mice. The 12 mice receiving 3-6 injections of anti-PD-L1 antibody showed a significant increase in the heart-to-tibial ratio and cardiomyoctye degeneration, hyalinization and extravascular inflammatory cell infiltration. In addition, the serum thyroxine was mardedly decreased to 1/3 of that in the control group mice, and the blood pressure and body temperature were abnormally decreased in mice upon treatment with PD-L1 blockade. Eight of the 12 (66.7%) mice died from multiple intravenous injection of anti-PD-L1 antibody.Intraperitoneal injection of levothyroxine 30 min before the injection of anti-PD-L1 antibody significantly attenuated the mortality rate of the anti-PD-L1 antibody-treated mice. CONCLUSION: The anti-PD-L1 antibody is cardiotoxic and lethal, and levothyroxine is able to rescue the mice from this immune checkpoint inhibitor-caused mortality. |
format | Online Article Text |
id | pubmed-8246393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-82463932021-07-13 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 Zhongguo Fei Ai Za Zhi 基础研究 BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) such as antibodies against programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have shown remarkable efficacies in many subtypes of cancers. However, ICIs may also cause severe immune-related adverse events in the recipient patients. Recently, ICI-associated myocarditis have been reported in hundreds of patients worldwide, with a mortality rate of approximately 50% in these cases. This study aims to recapitulate the cardiotoxicity and explore the detoxicifying approaches to attenuate mortality caused by PD-1/PD-L1 inhibitors in healthy mice. METHODS: Six to eight-week-old C57BL/6 mice were inoculated with anti-PD-1 antibody (12.5 μg/g every 5 days for 6 injections), anti-PD-L1 antibody (10 μg/g once a week for 6 weeks), anti-PD-L1 antibody (with the same dosage described above) in combination with levothyroxine (0.25 μg/g, intraperitoneally injected half an hour before anti-PD-L1 antibody injection), or isotype control immunoglobulin IgG (10 μg/g once a week for 6 weeks). The ejection function of the hearts was detected by echocardiography, body temperature and blood pressure were detected by Mouse Monitor(TM) and non-invassive blood pressure minotor, and serum free thyroxine concentration was detected by The enzyme linked immunosorbent assay (ELISA). RESULTS: PD-L1 was expressed at different levels by the cardiomyocytes of the mice. The isotype control immunoglobulin and anti-PD-1 antibody did not cause death of the mice. The 12 mice receiving 3-6 injections of anti-PD-L1 antibody showed a significant increase in the heart-to-tibial ratio and cardiomyoctye degeneration, hyalinization and extravascular inflammatory cell infiltration. In addition, the serum thyroxine was mardedly decreased to 1/3 of that in the control group mice, and the blood pressure and body temperature were abnormally decreased in mice upon treatment with PD-L1 blockade. Eight of the 12 (66.7%) mice died from multiple intravenous injection of anti-PD-L1 antibody.Intraperitoneal injection of levothyroxine 30 min before the injection of anti-PD-L1 antibody significantly attenuated the mortality rate of the anti-PD-L1 antibody-treated mice. CONCLUSION: The anti-PD-L1 antibody is cardiotoxic and lethal, and levothyroxine is able to rescue the mice from this immune checkpoint inhibitor-caused mortality. 中国肺癌杂志编辑部 2021-06-20 /pmc/articles/PMC8246393/ /pubmed/34157799 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.23 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 基础研究 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
title | 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
title_full | 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
title_fullStr | 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
title_full_unstemmed | 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
title_short | 抗PD-L1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
title_sort | 抗pd-l1抗体的心脏毒性及甲状腺素的救治作用实验研究 |
topic | 基础研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246393/ https://www.ncbi.nlm.nih.gov/pubmed/34157799 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.23 |
work_keys_str_mv | AT kàngpdl1kàngtǐdexīnzàngdúxìngjíjiǎzhuàngxiànsùdejiùzhìzuòyòngshíyànyánjiū AT kàngpdl1kàngtǐdexīnzàngdúxìngjíjiǎzhuàngxiànsùdejiùzhìzuòyòngshíyànyánjiū AT kàngpdl1kàngtǐdexīnzàngdúxìngjíjiǎzhuàngxiànsùdejiùzhìzuòyòngshíyànyánjiū AT kàngpdl1kàngtǐdexīnzàngdúxìngjíjiǎzhuàngxiànsùdejiùzhìzuòyòngshíyànyánjiū AT kàngpdl1kàngtǐdexīnzàngdúxìngjíjiǎzhuàngxiànsùdejiùzhìzuòyòngshíyànyánjiū AT kàngpdl1kàngtǐdexīnzàngdúxìngjíjiǎzhuàngxiànsùdejiùzhìzuòyòngshíyànyánjiū |